Sosei Group earnings date
Sosei Group (JSS) Q3 2026 Earnings Report
DE:JSS Q3 2026 EPS Results
- Actual EPS
- EUR 0.05
- Consensus EPS
- EUR 0.00
- Beat/Miss
- Beat by +EUR 0.04
- One Year Ago EPS
- -EUR 0.11
DE:JSS Q3 2026 Revenue Results
- Actual Revenue
- EUR 50.37M
- Expected Revenue
- EUR 46.62M
- Beat/Miss
- Beat by +EUR 3.75M
- YoY Revenue Growth
- +30.77%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/30/2026
- Time
- Before Open
- Conference Call
- Friday, October 30, 2026
Sosei Group's next earnings date is estimated for February 16, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, driven by 27% revenue growth, a return to profitability, growth in both marketed products, substantial milestone and partnered revenue, progress across multiple clinical programs, and maintained long-term targets. The main cautions were that profitability remains subject to milestone timing, partnership transactions are not yet completed, and QUVIVIQ revenue can fluctuate because of supply timing.
For 2026, Nxera guided to more than JPY 19.5 billion of sales from PIVLAZ and QUVIVIQ, at least one late-stage medicine for Japan and Asia Pacific, one or more high-value partnerships, at least 1 Phase II trial started by a partner, cutting costs by more than 10%, and profitability for the full year; core R&D is down 20% and core SG&A is down 11%. QUVIVIQ is expected to launch in Taiwan from the second half of this year and South Korea next year, vamorolone is planned for approval and launch during 2028 in Japan and South Korea, lucerastat has peak sales of over JPY 15 billion in Japan alone, with global NDA expected as early as 2029 and market launch in Japan planned for the early 2030s, and AGAMREE is expected to launch in Japan in 2028. The 2030 targets are unchanged at more than JPY 50 billion of revenue, an operating margin above 30%, and at least 5 products in Japan, with average growth of close to 10% per year; beyond 2030, Nxera aims for an operating margin of around 40% by 2035.
- Revenue Growth and Return to ProfitabilityNine-month revenue rose 27% year over year from JPY 21.8 billion to JPY 27.7 billion. Core operating profit was JPY 9.8 billion, already 126% of full-year guidance, while reported operating profit improved to JPY 3.2 billion from a JPY 5.9 billion loss a year earlier. IFRS operating profit was JPY 3.1 billion, including JPY 1.2 billion in Q3.
- Growth in Japan Commercial ProductsPIVLAZ sales increased 10% year over year to approximately JPY 9.9 billion for January through September, representing about 71% of the full-year target. QUVIVIQ sales increased 43% to JPY 4.5 billion, representing about 82% of its full-year target. Both products were described as being on track toward their full-year targets.
- Partnered Revenue and Milestone ProgressPartnered revenue increased 63% to JPY 13.3 billion, while total milestone revenue rose to JPY 11.8 billion from JPY 6.5 billion. Milestones were received as programs advanced with Neurocrine, Lilly, AbbVie and Centessa. Partnerships carry more than USD 4.5 billion in potential milestones plus royalties.
- Progress Against 2026 CommitmentsThe company reported progress on its five 2026 commitments: PIVLAZ and QUVIVIQ sales totaled JPY 14.4 billion after nine months, or 74% of the more than JPY 19.5 billion target; lucerastat delivered at least one late-stage medicine for Japan and Asia Pacific; three partner programs are moving into Phase II; and core R&D and core SG&A costs were down 20% and 11%, respectively. The company expects to be profitable for the full year.
- Lucerastat License for Fabry DiseaseNxera signed a license agreement with Idorsia for the development and commercialization of lucerastat in Japan and Asia Pacific, with an upfront payment of approximately JPY 1.3 billion. The oral Fabry disease treatment is late-stage, has more than six years of data, has orphan drug designation in the U.S. and EU, and is expected to have peak sales of more than JPY 15 billion in Japan. Global NDA submission is expected as early as 2029, with a Japan launch planned for the early 2030s.
- Vamorolone Development ProgressTop-line results from the GUARDIAN clinical trial for vamorolone showed markedly improved safety compared with corticosteroids. Regulators in Japan and Korea agreed that no additional clinical trials are needed before approval. The company completed filing in Korea this month, plans to file in Japan next year, and expects approval and launch in both countries during 2028.
- Expansion of QUVIVIQ in Asia PacificNxera signed a license agreement with Synmosa covering eight Asia Pacific countries. Product launches are expected in Taiwan from the second half of this year and in South Korea next year. Shionogi also revised its QUVIVIQ sales upward, which the company expects to provide a further boost to overall growth.
- Value of the Muscarinic PipelineSeven molecules from the UK discovery platform are in partners' clinical development, including one in Phase III. Direclidine is in Phase III for schizophrenia, alongside three other clinical muscarinic programs. These programs generated USD 32.5 million in milestones this year and have an overall value of USD 2.6 billion plus royalties. Phase III data for direclidine is expected in the second half of 2027.
- Orexin Portfolio Validation and ProgressThe FDA approved Takeda's first orexin agonist in narcolepsy type 1, which management described as validation of the biology. Lilly acquired Centessa in a transaction valued at approximately USD 6.3 billion, with a further USD 1.5 billion linked to approvals beyond narcolepsy type 1. Lilly is progressing three partnered molecules, and Nxera is eligible for milestones and low single-digit royalties across the portfolio globally.
- Discovery Platform Scale and EfficiencyThe NxWave platform includes more than 500 GPCR structures covering more than 62 receptors, over 30,000 stabilizing mutations and more than 5 million data sets. The company said hit-finding time has been reduced by 50% and hit-to-lead time by around 45% compared with historical data. Structures were generated for 69 receptors this year, 50% more than in 2025.
- AI-Enabled Drug DiscoveryNxera has incorporated AI, physics and experimental testing into a closed learning loop for drug discovery, using its GPCR structures, mutations, assay results and chemistry data. The company expects its first AI-designed molecules to undergo laboratory testing in the first half of 2027.
- Expansion of Oral and Specialty PipelineThe next wave of programs includes an amylin agonist for obesity, a TSHR negative allosteric modulator for Graves' disease and thyroid eye disease, and a PTH1R agonist for hypoparathyroidism. NXE'744 and NXE'149 have been brought to a Phase II-ready state, with active partnering discussions, while NXE'732 is in Phase IIa with Cancer Research UK and interim data is expected by the end of 2026.
- Long-Term Financial Targets MaintainedThe company maintained its 2030 targets of more than JPY 50 billion in revenue and an operating margin above 30%, compared with JPY 28.8 billion of revenue in FY 2024. Management also stated an objective of an operating margin of around 40% by 2035.
- Commercial Cost ManagementCommercial revenue progress was 74% of guidance while cost of goods progress was 66%. Management attributed the lower cost progress to ongoing cost-reduction activities and quarterly supply fluctuations, and said overall costs were being reduced compared with the beginning of the year.
- Planned Product Launches and MilestonesThe company expects to launch AGAMREE in Japan in 2028, begin lucerastat Phase III enrollment in 2027 including in Japan, report interim NXE'732 data by the end of 2026, and potentially announce a new partnership or licensing agreement for NXE'744 or NXE'149 by the end of this year.
- In-House Commercialization Strategy in JapanManagement said lucerastat is expected to be sold in-house in Japan, with commercial coverage potentially overlapping with the vamorolone sales network. For programs suited to Japan, such as the TSH and PTH programs, the company plans to develop and commercialize in Japan while seeking partners for worldwide rights outside Japan and Asia Pacific.
- Performance-Based Incentive PlanThe long-term incentive plan is designed to pay out only if shareholder value increases, with no realization for a minimum of three years. Management said the plan is intended to align employees and shareholders and support increased ownership by U.S. biotech institutions.
DE:JSS Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 16, 2027 | 2026 (Q4) | 0.35- | -0.49 | ― | ― |
| Oct 30, 2026 | 2026 (Q3) | 0.000.05 | -0.11 | 143.65% (+0.15) | |
| Aug 07, 2026 | 2026 (Q2) | -0.02-0.01 | -0.15 | 91.35% (+0.14) | |
| May 01, 2026 | 2026 (Q1) | ―0.11 | -0.05 | 334.56% (+0.16) | |
| Feb 13, 2026 | 2025 (Q4) | 0.42-0.49 | -0.08 | -475.30% (-0.40) | |
| Oct 31, 2025 | 2025 (Q3) | 0.13-0.11 | 0.08 | -237.47% (-0.18) | |
| Aug 08, 2025 | 2025 (Q2) | 0.10-0.15 | -0.09 | -66.58% (-0.06) | |
| May 02, 2025 | 2025 (Q1) | -0.23-0.05 | -0.21 | 76.96% (+0.16) | |
| Feb 14, 2025 | 2024 (Q4) | 0.05-0.08 | -0.01 | -480.02% (-0.07) | |
| Nov 01, 2024 | 2024 (Q3) | 0.000.08 | -0.34 | 122.45% (+0.42) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


